Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: SIRT-1 activators - RezGen5 Ltd

Next Previous
Drug Profile

Research programme: SIRT-1 activators - RezGen5 Ltd

Alternative Names: RezGen5

Latest Information Update: 16 Jul 2016

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeoMedigen
  • Developer RezGen5 Ltd
  • Class Carotenoids; Nicotinic acids; Polyphenols; Small molecules; Stilbenes; Zinc compounds
  • Mechanism of Action Cell cycle inhibitors; DNA repair enzyme stimulants; Free radical scavengers; Glycolysis inhibitors; Immunostimulants; Inflammation mediator inhibitors; Neuron modulators; Nicotinamide adenine dinucleotide modulators; Poly(ADP-ribose) polymerase modulators; SIRT1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer; Cardiovascular disorders; Neurodegenerative disorders; Obesity; Skin disorders; Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Bermuda
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Bermuda
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Bermuda

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top